TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration, low type 1 T-helper cell (T H 1) activity and reduced immune cytotoxicity or increased TGFβ levels predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden, T-cell exclusion and TGFβ-activated stroma. Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of the TGFβ signaling pathway promotes enough T cell infiltration to make tumors sensitive to PD-1 therapy [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“Cell analysis of human and mouse CRC specimens showed that CAF is a major contributor to TGF-β production [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“It has been demonstrated in a variety of tumor models, including CRC models, that activation of CAF may induce PD-1 and CTLA-4 expression on relevant immune cells, which leads to tumor insensitivity to immunotherapy or recurrence [39,304,305,306].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“A landmark study from 2018 demonstrated that TGF-β contributes to immune exclusion in colorectal liver metastasis and that inhibition of the TGF-β receptor 1 using the drug galunisertib enhanced tumorous infiltration with T cells, inhibited outgrowth of liver metastases and synergised with anti-PD-L1 therapy to eradicate established lesions.161”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [161]
In the citing paper
“leading to the proposition that combined TGFβ targeting and immune checkpoint blockade may represent an attractive therapeutic strategy for CMS4 colorectal cancer (34).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [34]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Items 801–900 of 1,002
Immunodivergence in Metastatic Colorectal Cancer
de Andrea, C. E., Schalper, K. A., Sanmamed, M. F., & Melero, I. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.012 · Cited by 34
Validation of Hepatocellular Carcinoma Experimental Models for TGF-β Promoting Tumor Progression
Mancarella, S., Krol, S., Crovace, A. M., Leporatti, S., Dituri, F., Frusciante, M., & Giannelli, G. (2019) · Cancers · doi:10.3390/cancers11101510 · Cited by 29
“The antitumor benefit observed was verified with greater expression of genes indicative of immune activation [60,61].”
BackgroundLin, C., Doi, T., Muro, K., Hou, M., Esaki, T., Hara, H., Chung, H. C., Helwig, C., Dussault, I., Osada, M., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00810-9 · Cited by 32
Shields, N. J., Peyroux, E. M., Ferguson, A. L., Steain, M. C., Neumann, S., & Young, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152035 · Cited by 33
Ye, F., Cai, Z., Wang, B., Zeng, C., Xi, Y., Hu, S., Qu, R., Yuan, Z., Yue, J., Tian, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3009 · Cited by 31
Emerging dimensions of autophagy in melanoma
Pangilinan, C. R., Klionsky, D. J., & Liang, C. (2024) · Autophagy · doi:10.1080/15548627.2024.2330261 · Cited by 32
Chen, E., Zeng, Z., & Zhou, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189198 · Cited by 37
A multistage drug delivery approach for colorectal primary tumors and lymph node metastases
Yuan, Y., Lin, Q., Feng, H., Zhang, Y., Lai, X. P., Zhu, M., Wang, J., Shi, J., Huang, Y., Zhang, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56768-z · Cited by 28
Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets
Li, Y., Liu, Q., Jing, X., Wang, Y., Jia, X., Yang, X., & Chen, K. (2025) · MedComm · doi:10.1002/mco2.70292 · Cited by 45
“Numerous influential clinical studies have demonstrated the therapeutic potential of these drugs, particularly when used in combination with immunotherapies such as anti-PD-1/PD-L1 [371, 372].”
Chen, X., Yang, M., Huang, Y., Tu, J., Cai, Y., & Yuan, X. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251387534 · Cited by 37
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga
Catalano, I., Grassi, E., Bertotti, A., & Trusolino, L. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.10.006 · Cited by 28
Neuroendocrine tumours and their microenvironment
de Hosson, L. D., Takkenkamp, T. J., Kats‐Ugurlu, G., Bouma, G., Bulthuis, M. L. C., de Vries, E. G. E., van Faassen, M. H. J. R., Kema, I. P., & Walenkamp, A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02556-1 · Cited by 29
The Paradoxical Roles of Inflammation during PD-1 Blockade in Cancer
Hill, M., Segovia, M., Russo, S., Girotti, M. R., & Rabinovich, G. A. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.09.003 · Cited by 27
Burvenich, I. J. G., Goh, Y. W., Guo, N. Y., Gan, H. K., Rigopoulos, A., Cao, D., Liu, Z., Ackermann, U., Wichmann, C. W., McDonald, A. F., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05251-0 · Cited by 28
IRF1 regulates the progression of colorectal cancer via interferon‑induced proteins
Xu, X., Wu, Y., Yi, K., Hu, Y., Ding, W., & Xing, C. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4937 · Cited by 30
“For metastatic tumor models, the specific humane endpoints were: Rapid weight loss or emacia‐ tion characterized by anemia, hunched posture, ungroomed appearance and lethargy (33).”
BackgroundPKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis
Linares, J. F., Zhang, X., Martínez-Ordóñez, A., Durán, Á., Kinoshita, H., Kasashima, H., Nakanishi, N., Nakanishi, Y., Carelli, R., Cappelli, L. V., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.039 · Cited by 30
Yang, L., Dong, X., Liu, Z., Tan, J., Huang, X., Wen, T., Qu, H., & Wang, Z. (2022) · eLife · doi:10.7554/elife.79811 · Cited by 32
Meliante, P. G., Barbato, C., Zoccali, F., Ralli, M., Greco, A., VINCENTIIS, M. D., Colizza, A., Petrella, C., Ferraguti, G., Minni, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315384 · Cited by 28
Wang, J., Dong, P., Qu, Y., Xu, W., Zhou, Z., Kang, N., Peng, Y., Xiong, L., Li, Z., Zou, X., et al. (2022) · European Radiology · doi:10.1007/s00330-022-09345-7 · Cited by 33
Zeng, M., Ruan, Z., Tang, J., Liu, M., Hu, C., Fan, P., & Dai, X. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02953-3 · Cited by 30
“Inhibition of TGF β induced a cytotoxic T-cell response to tumor cells, thus preventing metastasis [51].”
BackgroundNon‐viral gene delivery for cancer immunotherapy
Wang, W., Saeed, M., Zhou, Y., Yang, L., Wang, D., & Yu, H. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3092 · Cited by 30
“Blockade of TGF‐β can boost antitumor immunity and tumor regression.(67,68) Xu et al.”
BackgroundLeick, K. M., Rodriguez, A. B., Melssen, M. M., Benamar, M., Lindsay, R. S., Eki, R., Du, K., Parlak, M., Abbas, T., Engelhard, V. H., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003522 · Cited by 30
Targeting myeloid cells to improve cancer immune therapy
Chen, H., Xu, Z., & Varner, J. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1623436 · Cited by 41
Fibroblast Subsets in Intestinal Homeostasis, Carcinogenesis, Tumor Progression, and Metastasis
Dang, H., Harryvan, T. J., & Hawinkels, L. J. A. C. (2021) · Cancers · doi:10.3390/cancers13020183 · Cited by 26
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28
Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review
Juat, D. J., Hachey, S. J., Billimek, J., Rosario, M. P. D., Nelson, E. L., Hughes, C. C. W., & Zell, J. A. (2022) · The Oncologist · doi:10.1093/oncolo/oyab038 · Cited by 27
“3 12 (6-36) 6 4 (80) 4 (80) 2 (40) 1 (20) 11”
Román, M. S., Torres-Jiménez, J., Pozas, J., Esteban-Villarrubia, J., Albarrán, V., Ballesteros, P. Á., Chamorro-Pérez, J., Rodriguez, D. I. R., Orejana, I., Martínez-Delfrade, Í., et al. (2023) · Cancers · doi:10.3390/cancers15030863 · Cited by 31
Immunotherapy Targeting Tumor-Associated Macrophages
Liu, Y., & Wang, R. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.583708 · Cited by 28
Zhu, H., Xu, J., Wang, W., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105098 · Cited by 33
“15 However, the functional signi fi cance of B cells in PDAC remains unexplored.”
BackgroundCD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy
Feng, D., Pu, D., Ren, J., Liu, M., Zhang, Z., Liu, Z., & Li, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189193 · Cited by 33
Maddipati, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191943 · Cited by 37
Bou-Dargham, M. J., Liu, Y., Sang, Q. A., & Zhang, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207799 · Cited by 26
Marwitz, S., Ballesteros‐Merino, C., Jensen, S. M., Reck, M., Kügler, C., Perner, S., Drömann, D., Goldmann, T., & Fox, B. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001469 · Cited by 26
Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer
Dmello, R. S., To, S. Q., & Chand, A. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042067 · Cited by 30
PLAN B for immunotherapy: Promoting and leveraging anti-tumor B cell immunity
Shi, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.028 · Cited by 26
Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer
Lou, S., Wang, Y., Zhang, J., Yin, X., Zhang, Y., Wang, Y., & Xue, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.806324 · Cited by 28
“However, tumors with low DDR pathway signature scores were enriched with fibroblasts and endothelial cells, together with the TGF-b signaling pathway activation, corresponding to an immune-cold phenotype (69, 70).”
BackgroundChen, Z., Zhang, X., Xing, Z., Lv, S., Huang, L., Liu, J., Ye, S., Li, X., Chen, M., Zuo, S., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02324-8 · Cited by 28
Mukundan, A., Byeon, C., Hinck, C. S., Cunningham, K. T., Campion, T., Smyth, D. J., Maizels, R. M., & Hinck, A. P. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101994 · Cited by 22
“In the latter setting, TGF-β drives immune exclusion, which promotes cancer progression and can prevent effective checkpoint therapy (30, 31).”
BackgroundMatos, A. I., Peres, C., Carreira, B., Moura, L. I. F., Acúrcio, R. C., Vogel, T., Wegener, E., Ribeiro, F., Afonso, M. B., Santos, F. M. F., et al. (2023) · Advanced Science · doi:10.1002/advs.202300299 · Cited by 27
Mammary Stem Cells and Breast Cancer Stem Cells: Molecular Connections and Clinical Implications
Celià-Terrassa, T. (2018) · Biomedicines · doi:10.3390/biomedicines6020050 · Cited by 29
Riddiough, G. E., Fifis, T., Muralidharan, V., Perini, M. V., & Christophi, C. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14644 · Cited by 28
The Biology of Myxofibrosarcoma: State of the Art and Future Perspectives
Sambri, A., PAOLIS, M. D., Spinnato, P., Donati, D. M., & Bianchi, G. (2020) · Oncology Research and Treatment · doi:10.1159/000507334 · Cited by 24
Han, Y.-J., Shao, C.-Y., Yao, Y., Zhang, Z., Fang, M., Gong, T., Zhang, Y., & Li, M. (2024) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad136 · Cited by 27
Schmidt, D., Endres, C., Hoefflin, R., Andrieux, G., Zwick, M., Karantzelis, N., Staehle, H. F., Vinnakota, J. M., Duquesne, S., Jovein, M. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3553 · Cited by 29
“Previous work had shown that TGF-β can induce immunosuppression in the tumor microenvironment of colorectal cancer (12) and that it inhibits phosphorylation and activation of the Tec kinase Itk as well as NFATc translocation in T cells (13).”
Domingo, E., Rathee, S., Blake, A., Samuel, L. M., Murray, G. I., Sebag‐Montefiore, D., Gollins, S., West, N. P., Begum, R., Richman, S. D., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2024.105228 · Cited by 28
Current development of molecular classifications of gastric cancer based on omics (Review)
Ma, Y., Jiang, Z., Pan, L., Zhou, Y., Xia, R., Liu, Z., & Li, Y. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5677 · Cited by 35
Zhu, C., Liao, J.-Y., Liu, Y., Chen, Z., Chang, R.-Z., Chen, X., Zhang, B., & Liang, J.-N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02171-z · Cited by 29
Redirecting immune signaling with cytokine adaptors
Abhiraman, G. C., Householder, K. D., Rodriguez, G. E., Glassman, C. R., Saxton, R. A., Breuer, C. B., Wilson, S. C., Su, L., Yen, M., Hsu, C. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57681-1 · Cited by 30
“TGF-β suppresses T cell receptor signaling, cytotoxicity, and proliferation, in contrast to the effects of IL-2 36,37 (Fig.”
Centonze, A., Roura, A.-J., Novillo-Font, M., Giordano, C., Hernando‐Momblona, X., Llanses, M., Prats, P., Sevillano, M., Cabot, D., Novell, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0679 · Cited by 33
Self-citationBidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer
Ouahoud, S., Voorneveld, P. W., van der Burg, L. R. A., de Jonge‐Muller, E. S. M., Schoonderwoerd, M. J. A., Paauwe, M., de Vos, T. W., de Wit, S., van Pelt, G. W., Mesker, W. E., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1157-z · Cited by 26
Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers
Lindblad, K. E., de Galarreta, M. R., & Lujambio, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642958 · Cited by 28
“demonstrated that stromal cell-derived TGFß overexpression induces T cell exclusion as well as prevents acquisition of Th1 effector phenotype and resistance to anti-PD-1 immunotherapy in colon cancer (31) (Figure 1).”
BackgroundSingle-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
Lim, Y. W., Coles, G. L., Sandhu, S. K., Johnson, D. S., Adler, A. S., & Stone, E. L. (2021) · BMC Biology · doi:10.1186/s12915-021-01034-z · Cited by 29
Liu, Z.-L., Liu, J., Staiculescu, D., & Chen, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018026 · Cited by 27
A Signaling View into the Inflammatory Tumor Microenvironment
Pereira, J., Jordan, P., & Matos, P. (2021) · Immuno · doi:10.3390/immuno1020007 · Cited by 26
“Further targeting mechanisms, such as TGF-β signaling that activate CAFs or emanate from CAFs to modulate the tumor phenotype, are being intensively explored to treat colorectal cancer [23].”
BackgroundCannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy
Zaiachuk, M., Pryimak, N., Kovalchuk, O., & Kovalchuk, I. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.713153 · Cited by 30
Organ Specificity and Heterogeneity of Cancer-Associated Fibroblasts in Colorectal Cancer
Miyashita, N., & Saito, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010973 · Cited by 28
“In parallel, accumulating evidence suggests that activation of colorectal CAFs is associated with metastasis, therapeutic response and patient prognosis, underscoring their critical role in CRC progression [10,22,23].”
BackgroundTriggering Immune System With Nanomaterials for Cancer Immunotherapy
Liu, Y., Liu, Y., Huang, Z., Guo, Y., & Li, Q. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.878524 · Cited by 30
Autophagy Paradox: Strategizing Treatment Modality in Melanoma
Pangilinan, C. R., Xu, X., Herlyn, M., & Liang, C. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01053-8 · Cited by 25
Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer
Xiong, D., Wang, Y., & You, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-47382-3 · Cited by 33
Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes
Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 26
Francis, D. M., Manspeaker, M. P., Archer, P. A., Sestito, L. F., Heiler, A. J., Schudel, A., & Thomas, S. N. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121184 · Cited by 26
Chlorogenic acid and intestinal health: mechanistic insights and therapeutic applications
Xu, J., Zhao, X., Yang, S., Tang, M., Zhao, R., & Hu, S. (2025) · Food & Function · doi:10.1039/d5fo00853k · Cited by 28
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 37
“Finally, cancer associated fibroblasts express TGF-b, reducing T cell infiltration into the tumor environment through a similar mechanism as Treg cells([97,146-148]).”
BackgroundWang, Y., Yang, L., Dong, X., Yang, X., Zhang, X., Liu, Z., Zhao, X., & Wen, T. (2020) · BioMed Research International · doi:10.1155/2020/8216541 · Cited by 24
“TGF-β drives immune evasion by inhibiting CD4 T cell infiltration [41].”
BackgroundModelling TGFβR and Hh pathway regulation of prognostic matrisome molecules in ovarian cancer
Delaine‐Smith, R. M., Maniati, E., Malacrida, B., Nichols, S., Roozitalab, R., Jones, R. R., Lecker, L. S. M., Pearce, O. M. T., Knight, M. M., & Balkwill, F. R. (2021) · iScience · doi:10.1016/j.isci.2021.102674 · Cited by 27
microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3
Li, Y., Zhou, T. Y., Cheng, X., Li, D., Zhao, M., & Zheng, W. (2022) · Bioengineered · doi:10.1080/21655979.2022.2031408 · Cited by 25
Li, J., & Zhao, X. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12649 · Cited by 29
Deng, Y., Zhao, L., Huang, X., Zeng, Y., Xiong, Z., & Zuo, M. (2022) · Nutrition · doi:10.1016/j.nut.2022.111829 · Cited by 31
Fuertes, G., del Valle‐Pérez, B., Pastor, J., Andrades, E., Peña, R., de Herreros, A. G., & Duñach, M. (2023) · EMBO Reports · doi:10.15252/embr.202254895 · Cited by 26
Oka, T., Higa, T., Sugahara, O., Koga, D., Nakayama, S., & Nakayama, K. I. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2578 · Cited by 25
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Hoeijmakers, L. L., Reijers, I. L. M., & Blank, C. U. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0352 · Cited by 28
Zhou, C., & Zhang, J. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0685-9 · Cited by 24
Antitumor T‐cell function requires CPEB4‐mediated adaptation to chronic endoplasmic reticulum stress
Fernández‐Alfara, M., Sibilio, A., Martín, J., Uxó, E. T., Malumbres, M., Alcalde, V., Chanes, V., Cañellas-Socias, A., Palomo‐Ponce, S., Batlle, E., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022111494 · Cited by 25
Self-citationYen, Y., Zhang, Z., Chen, A., Qiu, Y., Liu, Q., Wang, Q., Li, C., Wang, C., Qian, X., Shao, J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03129-z · Cited by 25
Emerging Complexity in CD4+T Lineage Programming and Its Implications in Colorectal Cancer
Ditoro, D. F., & Basu, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694833 · Cited by 25
Ros, J., Baraibar, I., Martini, G., Salvà, F., Gonzalez, N. S., Cuadra‐Urteaga, J. L., Dienstmann, R., Tabernero, J. M., & Élez, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00913-5 · Cited by 25
Ma, X., Luo, Y.-F., Zeng, F.-F., Su, C., Liu, X., Li, X., & Lü, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.815437 · Cited by 36
Bresser, K., Logtenberg, M. E. W., Toebes, M., Proost, N., Sprengers, J., Siteur, B., Boeije, M., Kroese, L. J., & Schumacher, T. N. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2049486 · Cited by 24
Xie, L., Liu, M., Cai, M., Huang, W., Guo, Y., Liang, L., Cai, W., Liu, J., Liang, W., Tan, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114254 · Cited by 26
Tanjak, P., Chaiboonchoe, A., Suwatthanarak, T., Acharayothin, O., Thanormjit, K., Chanthercrob, J., Suwatthanarak, T., Wannasuphaphol, B., Chumchuen, K., Suktitipat, B., et al. (2023) · Cancers · doi:10.3390/cancers15041098 · Cited by 27
“The EMT signaling pathway was regulated by TGFβ signaling, which plays a key role in the progression of colorectal cancer by evading the immune system [15,29,30].”
BackgroundColorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment
Liu, Q.-L., Zhou, H., Zhou, Z., & Chen, H. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10107-0 · Cited by 26
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated
Karami, Z., Mortezaee, K., & Majidpoor, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110648 · Cited by 26
Kim, W., Zhou, Y., Simonenko, V., Shahi, A., Malikzay, A., Long, S. Z., Xu, J. J., Lu, A., Horng, J.-H., Wu, C., et al. (2024) · NAR Cancer · doi:10.1093/narcan/zcad059 · Cited by 32
“In colorectal cancer ( CRC ) , in mice with progressive liver metastatic disease, blockade of TGF β signaling rendered tumors susceptible to anti-PD-1 / PD-L1 therapy ( 10 ) .”
BackgroundMethodInfluentialStrait, A. A., & Wang, X. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23196 · Cited by 25
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy
Nejad, E. B., Labrie, C., Abdulrahman, Z., van Elsas, M. J., Rademaker, E., Kleinovink, J. W., van der Sluis, T. C., van Duikeren, S., Teunisse, A. F. A. S., Jochemsen, A. G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001326 · Cited by 25
Microenvironmental regulation of tumour immunity and response to immunotherapy
Kockx, M. M., McCleland, M. L., & Koeppen, H. (2021) · The Journal of Pathology · doi:10.1002/path.5681 · Cited by 28
“Tauriello et al demonstrated that mutant mice develop locally advanced and metastatic tumours with an immune-excluded phenotype, accumulation of PD1 T-cells, PD-L1 stromal cells, and evidence of active TGF-β signalling [63].”
BackgroundSingle‐cell advances in stromal‐leukocyte interactions in cancer
Wu, S. Z., & Swarbrick, A. (2021) · Immunological Reviews · doi:10.1111/imr.12976 · Cited by 22
Strait, A. A., Woolaver, R. A., Hall, S. C., Young, C. D., Karam, S. D., Jimeno, A., Lan, Y., Raben, D., Wang, J. H., & Wang, X. (2021) · Communications Biology · doi:10.1038/s42003-021-02522-2 · Cited by 22
Arany, P. R. (2021) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2021.0109 · Cited by 32
Prognostic value of the PrP C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype
Ghazi, A., Le Corre, D., Pilati, C., Taieb, J., Aparicio, T., Didelot, A., Dedhar, S., Mulot, C., Le Malicot, K., Djouadi, F., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1940674 · Cited by 21
“Notably, PrP operates through the mobilization of the YAP/TAZ and TGFß pathways,(5) the latter being actively scrutinized for its contribution to CRC metastasis.(6,7) In the present study, we aimed at further investigating the molecular pathways downstream from PrP in CMS4 CRC.”
BackgroundLiver Metastasis in Cancer: Molecular Mechanisms and Management
Xu, W., Xu, J., Liu, J., Wang, N., Zhou, L., & Guo, J. (2025) · MedComm · doi:10.1002/mco2.70119 · Cited by 31
Impact of radiation therapy on the immunological tumor microenvironment
Guilbaud, E., Naulin, F., Meziani, L., Deutsch, É., & Galluzzi, L. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.001 · Cited by 28
Advancing CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress
Smirnov, S., Zaritsky, Y., Silonov, S. A., Gavrilova, A. A., & Fonin, A. V. (2025) · Biomolecules · doi:10.3390/biom15101407 · Cited by 23
TGF-β in tumor development and progression: mechanisms and therapeutics
Liu, J., Wang, Y., Tang, C., Zhang, L., Xiong, S., Wang, J., & Dong, C. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00403-w · Cited by 31
Viral Hepatitides, Inflammation and Tumour Microenvironment
Timperi, E., & Barnaba, V. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-44518-8_3 · Cited by 21
A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
Huang, Q., Lei, Y., Li, X., Guo, F., & Liu, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580140 · Cited by 25
“Combination of TGF-β inhibitors and immunotherapy can enhance the anti-tumor effect of TGF-β inhibition and significantly increase the survival rate of tumorbearing mice (Tauriello et al., 2018).”
BackgroundHepsin regulates TGFβ signaling via fibronectin proteolysis
Belitškin, D., Pant, S. M., Munne, P., Suleymanova, I., Belitškina, K., Hongisto, H., Englund, J. I., Raatikainen, T., Klezovitch, O., Vasioukhin, V. I., et al. (2021) · EMBO Reports · doi:10.15252/embr.202152532 · Cited by 23
Leveraging cellular mechano-responsiveness for cancer therapy
Hyun, J., & Kim, H. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.11.006 · Cited by 23
Varricchio, L., & Hoffman, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906698 · Cited by 29
“TGFb1 is the driver and primary mediator of changes in the tumor microenvironment and is a critical factor that limits the efficacy of checkpoint inhibitor therapy for patients with several types of solid tumors (9, 10).”
Background
Metadata
- Authors
- Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Universitat Autònoma de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Batlle, Eduard
- ORCID
- Venue
- Nature
- Published
- 2018-02
- Volume
- 554
- Issue
- 7693
- Pages
- 538-543
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2788975052
- Cited by
- 1,851
- References
- 43
- Citations by year
- 2026: 193 · 2025: 186 · 2024: 159 · 2023: 211 · 2022: 280 · 2021: 305 · 2020: 247 · 2019: 176 · 2018: 94
- FWCI
- 77.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta signaling, colorectal cancer metastasis, immune evasion, T-cell exclusion, tumor microenvironment, immune checkpoint inhibitors, TGF-beta inhibition, liver metastasis, microsatellite stable colorectal cancer, genetically engineered mouse models, organoid transplantation, combination immunotherapy
- MeSH terms
- Alleles, Animals, Cell Differentiation, Colonic Neoplasms, Disease Models, Animal, Drug Synergism, Female, Humans, Immunotherapy, Intestinal Mucosa, Intestines, Liver Neoplasms, Male, Mutation, Neoplasm Metastasis, Stem Cells, T-Lymphocytes, Cytotoxic, Transforming Growth Factor beta, Th1 Cells, Mice, Immune Evasion, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.